Treatment of dementia associated with Parkinson's disease

Aarsland, 2005, A systematic review of prevalence studies of dementia in Parkinson's disease, Mov Disord, 20, 1255, 10.1002/mds.20527 Hely, 2005, Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years, Mov Disord, 20, 190, 10.1002/mds.20324 Emre, 2003, What causes mental dysfunction in Parkinson's disease?, Mov Disord, 18, S63, 10.1002/mds.10565 Emre, 2003, Dementia associated with Parkinson's disease, Lancet Neurol, 2, 229, 10.1016/S1474-4422(03)00351-X Pillon, 2001, Cognitive deficits and dementia in Parkinson's disease, 311 Whitehouse, 1983, Basal forebrain neurons in the dementia of Parkinson disease, Ann Neurol, 13, 243, 10.1002/ana.410130304 Perry, 1985, Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease, J Neurol Neurosurg Psychiatry, 48, 413, 10.1136/jnnp.48.5.413 Perry, 1987, Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases, J Neural Transm Suppl, 24, 131 Tiraboschi, 2000, Cholinergic dysfunction in diseases with Lewy bodies, Neurology, 54, 407, 10.1212/WNL.54.2.407 Bohnen, 2003, Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study, Arch Neurol, 60, 1745, 10.1001/archneur.60.12.1745 Bohnen, 2006, Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia, J Neurol, 253, 242, 10.1007/s00415-005-0971-0 Aarsland, 2004, Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy Bodies, J Geriatr Psychiatry Neurol, 17, 164, 10.1177/0891988704267463 Emre, 2004, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med, 351, 2509, 10.1056/NEJMoa041470 Poewe, 2005, Long- term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study, Mov Disord, 21, 456, 10.1002/mds.20700 Burn, 2006, Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease, Mov Disord, 21, 1899, 10.1002/mds.21077 Wesnes, 2005, Benefits of rivastigmine on attention in dementia associated with Parkinson disease, Neurology, 65, 1654, 10.1212/01.wnl.0000184517.69816.e9 Bronnick, 2006, Attentional deficits affect activities of daily living in dementia associated with Parkinson's disease, J Neurol Neurosurg Psychiatry, 77, 1136, 10.1136/jnnp.2006.093146 Dubois B, Tolosa E, Kulisevsky J, Reichman H, Jones R, Burn D, et al. Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. Poster presented at AD-PD, March 14–18 2007, Salzburg. Ridha, 2005, Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine, Neurology, 65, 481, 10.1212/01.wnl.0000172351.95783.8e Sabbagh, 2005, The use of memantine in dementia with Lewy bodies, J Alzheimer's Dis, 7, 285, 10.3233/JAD-2005-7403 Fox, 2005, Memantine in Parkinson's disease dementia: clinical experience, Mov Disorders, 20, P418 Sharma, 2007, Cognitive effects of safinamide in early Parkinson's disease (PD) patients, Mov Disord, 22, S236 Aarsland, 2007, Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress, J Neurol Neurosurg Psychiatry, 78, 36, 10.1136/jnnp.2005.083113 1999, Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease, N Engl J Med, 340, 757, 10.1056/NEJM199903113401003 1999, Clozapine in drug-induced psychosis in Parkinson's disease, Lancet, 353, 2041, 10.1016/S0140-6736(99)00860-0 Ondo, 2002, Olanzapine treatment for dopaminergic-induced hallucinations, Mov Disord, 17, 1031, 10.1002/mds.10217 Breier, 2002, Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease, Biol Psychiatry, 52, 438, 10.1016/S0006-3223(02)01392-6 Ellis, 2000, Clozapine and risperidone treatment of psychosis in Parkinson's disease, J Neuropsychiatry Clin Neurosci, 12, 364, 10.1176/jnp.12.3.364 Friedman, 2002, Atypical antipsychotics in Parkinson- sensitive populations, J Geriatr Psychiatry Neurol, 15, 156, 10.1177/089198870201500307 Morgante, 2004, Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis, Clin Neuropharmacol, 27, 153, 10.1097/01.wnf.0000136891.17006.ec Fernandez, 2003, Long-term outcome of quetiapine use for psychosis among Parkinsonian patients, Mov Disord, 18, 510, 10.1002/mds.10374 Goetz, 2002, Drugs to treat dementia and psychosis, Mov Disord, 17, 120 Weintraub, 2005, Antidepressant studies in Parkinsons's disease: a review and meta-analysis, Mov Disord, 20, 1161, 10.1002/mds.20555 Miyasaki, 2006, Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 66, 996, 10.1212/01.wnl.0000215428.46057.3d Hogl, 2002, Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, cross-over, placebo-controlled, polygraphic trial, Sleep, 25, 905, 10.1093/sleep/25.8.62 Adler, 2003, Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease, Mov Disord, 18, 287, 10.1002/mds.10390 Nieves, 2002, Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil, Clin Neuropharmacol, 25, 111, 10.1097/00002826-200203000-00010 Ondo, 2005, Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial, J Neurol Neurosurg Psychiatry, 76, 1636, 10.1136/jnnp.2005.065870